Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.

Although bleeding time is the most frequently used measure of global platelet function, this test has important disadvantages.

In vitro closure time (CT) is a relatively new and efficient test of primary hemostasis.

The researchers designed a prospective randomized study to evaluate the effect of desmopressin on platelet function, as measured by in vitro CT, in uremic patients.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

Forty-eight uremic patients, about to commence hemodialysis and with prolonged CT, were randomized to infusion with desmopressin (n = 24) or saline alone (n = 24).

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

Complete blood count, prothrombin time, activated partial thrombin time, levels of plasma fibrinogen, von Willebrand factor (VWF), factor VIII (FVIII) and CT were measured before and 1 h after desmopressin or saline infusion.

What Was Measured

The subject headings attached to it are Blood Platelet Disorders, Blood Platelets, Deamino Arginine Vasopressin, Hemostasis, Platelet Count and Uremia.

What This Means in Plain Language

The paper is a randomized study of Vasopressin and Desmopressin.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Nephron. Clinical practice), a journal based in Switzerland.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.